Emergent BioSolutions Inc. (LON:0IGA)
8.23
-0.05 (-0.65%)
At close: Sep 12, 2025
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $140.90M USD in the quarter ending June 30, 2025, a decrease of -44.68%. This brings the company's revenue in the last twelve months to $851.60M, down -22.74% year-over-year. In the year 2024, Emergent BioSolutions had annual revenue of $1.04B, down -0.54%.
Revenue (ttm)
$851.60M
Revenue Growth
-22.74%
P/S Ratio
0.49
Revenue / Employee
$946.22K
Employees
900
Market Cap
306.10M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Emergent BioSolutions News
- 8 days ago - Emergent BioSolutions (EBS) Secures $56 Million Contract for ACAM2000 - GuruFocus
- 8 days ago - Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness - GlobeNewsWire
- 14 days ago - Emergent BioSolutions (EBS) Maintains Buy Rating and Price Target | EBS Stock News - GuruFocus
- 15 days ago - Emergent Biosolutions awarded $30 million contract modification for CYFENDUS - Seeking Alpha
- 15 days ago - Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use - GlobeNewsWire
- 19 days ago - Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day - GlobeNewsWire
- 21 days ago - Emergent BioSolutions to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 27 days ago - Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™ - GlobeNewsWire